Sobi welcomes new CEO

Swedish Orphan Biovitrum (Sobi) has appointed Guido Oelkers as President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough. 

Prior to this position Guido Oelkers held position of CEO at BSN Medical GmbH.

“Guido is the right person to further develop Sobi’s strategy as a pioneering biotechnology company, expanding upon the journey for our successful global brands, and realise the remarkable potential in our haemophilia franchise,” said Håkan Björklund, Chairman of Sobi.

To remind, on Wednesday Sobi reported that it has opened a new haemophilia research office in Athens, Greece.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.